Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT3B4G)

Drug Name

MEDI-500 Drug Info

Synonyms

T10B9; T10B9.1A31

Indication

Disease Entry	ICD 11	Status	REF
Bone marrow transplantation	QB63.6	Terminated	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Regulatory protein unspecific (RGP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teplizumab	DMZ3P6C	Type-1 diabetes	5A10	Approved	[3]
Visilizumab	DMXYM1H	Graft-versus-host disease	4B24	Phase 3	[4]
NI-0401	DMEOLVP	Autoimmune diabetes	5A10	Phase 1/2	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Regulatory protein unspecific (RGP)	TTBMAOZ	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006835)
2	T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action. Clin Transplant. 1996 Dec;10(6 Pt 2):607-13.
3	Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010 Oct;40(10):2891-901.
4	Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9.
5	Clinical pipeline report, company report or official report of NovImmune.